XELA REDERM® 1.8% ( 1 x 2.0 mL) | Institute Hyalual (Switzerland)

Short Description

A core restorative cellular redermalizer combining 1.8% (18 mg/mL) High-Molecular-Weight Non-Cross-Linked Hyaluronic Acid with 1.6% (16 mg/mL) Sodium Succinate (Succinic Acid). Calibrated for mid-to-deep dermal biorevitalization in patients aged 35+, XELA REDERM® 1.8% treats moderate photo- and chrono-aging, dehydrated and devitalized skin, fine-to-medium wrinkles, and cutaneous laxity across the face, neck, and décolletage—restoring mitochondrial ATP respiration, microvascular circulation, and dermal turgor with clinical results lasting 6 to 9 months.

Detailed Description

XELA REDERM® 1.8% is an advanced, sterile, non-pyrogenic physiological injectable developed in Switzerland by Institute Hyalual. Functioning as the foundational workhorse of the Xela Rederm family, it is calibrated for patients aged 35 and older who exhibit clear clinical signs of skin fatigue, structural elastosis, dehydration, and early-to-moderate gravitational soft-tissue descent.

The formulation utilizes the proprietary Redermalization mechanism, addressing the cellular roots of skin aging rather than providing temporary surface hydration alone:

1. High-Molecular-Weight Hyaluronic Acid (1.8% / 18 mg/mL): Pure, uncross-linked sodium hyaluronate creates an optimal physiological microenvironment within the extracellular matrix (ECM). At 18 mg/mL, it provides structural hydration, restores skin turgor, and acts as an intercellular delivery scaffold that facilitates the continuous intracellular uptake of succinate ions without hydrophilic over-expansion or tissue stiffness.

2. Sodium Succinate (1.6% / 16 mg/mL): A crucial biochemical intermediate that acts directly upon Complex II of the mitochondrial electron transport chain (the Krebs cycle). By restoring cellular respiration and upregulating ATP synthesis, succinate reactivates senescent and metabolically exhausted fibroblasts. This metabolic acceleration drives de novo synthesis of Type I and Type III collagen, strengthens native elastin fibers, stimulates microvascular perfusion and lymphatic drainage, and provides direct antioxidant neutralization of tissue-damaging free radicals.

Positioned between the delicate 1.1% periorbital formulation and the dense 2.2% structural lifting matrix, Xela Rederm 1.8% provides the optimal balance of spreadability, viscosity, and lifting capacity for broad facial and cervical redensification.

Treatment Areas & Indications

• Full-Face Biorevitalization & Photoaging (Patients Aged 35+):

  • Chronically dehydrated, dull, sallow, or “smoker’s skin” lacking microcirculatory flush

  • Moderate static and dynamic facial rhytids (forehead creases, glabellar lines, accordion smile lines)

  • Loss of dermal elasticity, cutaneous thinning, and generalized tissue fatigue

• Perioral & Lower Face Rejuvenation:

  • Radial perioral rhytids (“smoker’s lines” / barcode lines)

  • Mild-to-moderate nasolabial folds and marionette depressions

• Neck & Décolletage Redermalization:

  • Transverse cervical wrinkles (“necklace bands”) and horizontal neck rings

  • Thin, sun-damaged, crepey skin and sleep-induced creases across the décolleté

• Dorsal Hand Rejuvenation:

  • Restoring dermal density and concealing exposed veins and tendons on aging hands

• Post-Traumatic & Post-Procedure Skin Optimization:

  • Improving the texture of atrophic post-acne scarring and striae distensae

  • Pre- and post-conditioning for chemical peels, laser skin resurfacing, and plastic surgery

Key Clinical Advantages

• The Core “Workhorse” Concentration: 1.8% HA concentration provides noticeable dermal redensification and hydraulic smoothing without the heaviness or prolonged papule persistence of denser fillers.

• Mitochondrial ATP Reactivation: Fuels the Krebs cycle directly to reverse intracellular hypoxia and accelerate cellular turnover.

• Capillary Perfusion & Lymphatic Clearance: Decongests sluggish tissue beds, improving the natural microcirculatory flush and clearing cellular metabolic debris.

• Zero BDDE / High Biocompatibility: 100% free of synthetic chemical cross-linkers, eliminating risks of late-onset granulomatous reactions or chronic encapsulation.

• Dual Technique Utility: Compatible with classical micro-papular mesotherapy protocols as well as blunt-cannula retrograde fanning across facial vectors.

• Extended Cellular Durability: While the uncross-linked HA matrix integrates over weeks, the newly synthesized collagen framework sustains improved firmness and tone for 6 to 9 months.

Technical Specifications

Professional Advisory: XELA REDERM® 1.8% is a CE Class III medical device intended strictly for certified dermatologists, plastic surgeons, and credentialed aesthetic physicians trained in intradermal injection techniques. In the thin, translucent periorbital/lower-eyelid zone, Xela Rederm 1.1% should be used instead to prevent prolonged visible papules.